We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00292045
First Posted: February 15, 2006
Last Update Posted: June 22, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Ludwig Institute for Cancer Research
February 13, 2006
February 15, 2006
June 22, 2009
December 2004
Not Provided
to assess the safety of intradermal immunization with NY-ESO-1 protein combined with CpG 7909 in patients with high-risk stage D1 or advanced prostate cancer
Same as current
Complete list of historical versions of study NCT00292045 on ClinicalTrials.gov Archive Site
  • to evaluate the immunity induced after intradermal immunization with NY-ESO-1 protein combined with CpG 7909 in patients with high-risk stage D1 or advanced prostate cancer
  • to document tumor response following intradermal immunization with NY-ESO-1 protein combined with CpG 7909
Same as current
Not Provided
Not Provided
 
Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer
Phase 1 Study of Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With High-Risk Stage D1 or Advanced Prostate Cancer

This is an open-label, fixed-dose study of immunization with NY-ESO-1 protein combined with CpG as adjuvant in patients with high-risk stage D1 or advanced prostate cancer

Eligible patients will receive vaccinations consisting of 100µg NY-ESO-1 protein combined with 2.5mg CpG administered intradermally every 3 weeks for 4 doses.

This is an open-label, fixed-dose study of immunization with NY-ESO-1 protein combined with CpG 7909 as adjuvant in patients with histopathologically confirmed metastatic cancer of the prostate, who have progressive disease under hormonal and/or chemotherapeutic treatment (duration of treatment > 3 months).

Eligible patients will receive vaccinations consisting of 100µg NY-ESO-1 protein combined with 2.5 mg CpG 7909 administered intradermally every 3 weeks for 4 doses. Twelve (12) patients will be enrolled into this study.

Blood samples will be obtained at baseline, prior to the second, third and fourth injection and three weeks after the fourth injection for clinical hematology, biochemistry and immune response assessments. Blood samples for antinuclear antibody (ANA) and anti-dsDNA will be collected at baseline and end of each study cycle.

A tumor sample, resected prior to immunization, will be tested to determine NY-ESO-1 and/or LAGE-1 expression.

DTH testing will be performed with NY-ESO-1b in HLA-A2+ patients and with NY-ESO-1 DP4 in HLA-DP4+ patients at baseline and at the 3-week visit following the second and fourth vaccinations.

NY-ESO-1 and/or LAGE-1 specific antibodies will be assessed in all patients by Western Blot and ELISA. NY-ESO-1 specific CD4+ and CD8+ T cells will be assessed by ELISPOT analysis in all patients.

Disease status will be assessed at baseline and 3 weeks after the fourth vaccination in patients with measurable disease.

Patients who demonstrate stable disease, minor response, partial response, or complete response on week 13 may continue to receive vaccinations until disease progression. In patients with mixed response, single progressive lesions may be resected and vaccination may be continued.

Resected metastases should be typed for NY-ESO- and/or LAGE-1 expression.

Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Prostate Cancer
Biological: NY-ESO-1 protein/CpG
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
12
January 2006
Not Provided

Inclusion Criteria:

  1. Patients must have high-risk stage D1 or metastatic prostate cancer (D2), confirmed by review of histology.
  2. Patients must have fully recovered from surgery.
  3. Patients must show stable or progressive disease as assessed by X-ray, ultrasound, and/or CT scans under hormonal and/or chemotherapeutic treatment, that had been administered for at least three months.
  4. Any pretreatment with chemo- or radiotherapy must have been discontinued for at least four weeks prior to first dose of study agent. Hormone therapy is allowed before and throughout the study.
  5. Patients must have an expected survival of at least three months.
  6. Patients must have a Karnofsky performance status of 70% or more.
  7. Within the last 2 weeks prior to study day 1, vital laboratory parameters should be within normal range, except for the following laboratory parameters, which should be within the ranges specified:

    • Leukocytes >3.000/ul
    • Lymphocytes >700/ul
    • Platelets >100.000/ul
    • Serum creatinine <2.5 mg/dl
    • ALT, AST, and total bilirubin all < 2.5 x ULN
  8. Age ≥ 18 years
  9. Able to give valid written informed consent.

Exclusion Criteria:

  1. Clinically significant heart disease (NYHA Class III or IV).
  2. Other serious illnesses, eg, active infections requiring antibiotics, bleeding disorders.
  3. Concomitant systemic treatment with corticosteroids. Topical or inhalational steroids are permitted.
  4. Metastatic disease to the central nervous system.
  5. Mental impairment, in the opinion of the investigator, that may compromise the ability to give informed consent and comply with the requirements of the study.
  6. Lack of availability for immunological and clinical follow-up assessments.
  7. Participation in chemotherapy, radiation therapy, or any other clinical trial involving another investigational agent within 4 weeks prior to first dosing.
  8. Being a recipient of an organ or bone marrow allograft. Having an autoimmune disease other than vitiligo, such as, but not limited to, inflammatory bowel disease or multiple sclerosis.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Germany,   Switzerland
 
 
NCT00292045
LUD2003-024
2004DR1380 (SwissMedic)
KEK-StV-Nr. 01/04 (local EC)
Not Provided
Not Provided
Not Provided
Not Provided
Ludwig Institute for Cancer Research
Not Provided
Principal Investigator: Alexander Knuth, Prof. Dr. med. Clinic of Oncology, University Hospital Zürich, Switzerland
Principal Investigator: Elke Jäger, Prof. Dr. med. II. Medizinische Klinik, Hämatologie/Onkologie, Krankenhaus Nordwest, Frankfurt
Ludwig Institute for Cancer Research
June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP